Merck: Executive Board Member Oschmann Elected President of IFPMA

Presidency at IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) under overarching theme of “Accelerating Access”

06-Nov-2014 - Switzerland

Stefan Oschmann, CEO Pharma and Member of the Executive Board of Merck, was elected President of IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) during 27th IFPMA Assembly in New York, U.S.A. The term of office of Oschmann, who has been Vice President at IFPMA since 2012, runs two years. He succeeds John Lechleiter, Chairman, President and CEO of the Executive Board of Eli Lilly and Co.

“I plan to focus my presidency on ‘accelerating access’ to quality health solutions for people in low and middle income countries to contribute to the sustainability challenge,” Oschmann said. “Much progress has been achieved in expanding access to health in these countries but the call for ‘accelerating access’ demonstrates that there is still so much that needs to be done and only together can we make a lasting difference.”

During his speech Oschmann underscored the priority areas which will contribute to the Sustainable Development Goals Agenda and his overarching mandate of ‘accelerating access’: “Recognizing and nurturing innovation through local entrepreneurship in low and middle income countries is one of the principal ways we can contribute to accelerating access. The need for stronger health systems in these countries and for building healthcare capacities through local empowerment is one area where we can also help to accelerate access. The Ebola crisis is clearly a case in point. Addressing gaps and challenges in tackling the current Non-Communicable Disease epidemic is another way we can help these countries to accelerate access and overcome the burden posed by chronic diseases.”

https://www.bionity.com/en/news/150379/merck-executive-board-member-oschmann-elected-president-of-ifpma.html